Revvity, Inc. (NYSE:RVTY) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. decreased its holdings in Revvity, Inc. (NYSE:RVTY - Free Report) by 22.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 268,205 shares of the company's stock after selling 75,910 shares during the period. JPMorgan Chase & Co. owned 0.22% of Revvity worth $29,934,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Assetmark Inc. boosted its stake in shares of Revvity by 3,700.0% during the 4th quarter. Assetmark Inc. now owns 266 shares of the company's stock worth $30,000 after purchasing an additional 259 shares during the period. Millstone Evans Group LLC purchased a new position in shares of Revvity during the fourth quarter valued at approximately $38,000. Continuum Advisory LLC grew its stake in shares of Revvity by 2,972.7% during the third quarter. Continuum Advisory LLC now owns 338 shares of the company's stock valued at $43,000 after buying an additional 327 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Revvity by 55.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock worth $43,000 after buying an additional 138 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Revvity by 33.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company's stock worth $58,000 after acquiring an additional 131 shares during the last quarter. Hedge funds and other institutional investors own 86.65% of the company's stock.

Remove Ads

Revvity Stock Up 1.8 %

NYSE:RVTY traded up $1.67 during trading hours on Friday, reaching $94.69. The company's stock had a trading volume of 2,420,772 shares, compared to its average volume of 885,747. The stock has a 50 day moving average price of $109.12 and a two-hundred day moving average price of $115.09. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The company has a market capitalization of $11.38 billion, a P/E ratio of 42.84, a price-to-earnings-growth ratio of 3.82 and a beta of 1.07. Revvity, Inc. has a 12 month low of $89.61 and a 12 month high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the previous year, the company posted $1.25 earnings per share. Equities analysts predict that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date is Thursday, April 17th. Revvity's dividend payout ratio is currently 12.67%.

Insider Transactions at Revvity

In other news, insider Joel S. Goldberg sold 15,170 shares of the firm's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the sale, the insider now owns 33,400 shares of the company's stock, valued at $4,232,782. This trade represents a 31.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.68% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on RVTY shares. Raymond James reiterated an "outperform" rating and issued a $145.00 target price (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Barclays cut their price target on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a report on Thursday. KeyCorp lifted their price objective on shares of Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Finally, Sanford C. Bernstein downgraded shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 target price on the stock. in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $133.75.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.